← Back to Screener
NRX Pharmaceuticals, Inc. Common Stock (NRXP)
Price$3.20
Favorite Metrics
Price vs S&P 500 (26W)-4.33%
Price vs S&P 500 (4W)72.65%
Market Capitalization$105.82M
All Metrics
Book Value / Share (Quarterly)$1.12
P/TBV (Annual)3.61x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)14.15%
EPS (TTM)$-1.57
10-Day Avg Trading Volume1.23M
EPS Excl Extra (TTM)$-1.57
EPS (Annual)$-1.34
ROI (Annual)-221.67%
Gross Margin (Annual)58.78%
Cash / Share (Quarterly)$0.25
ROA (Last FY)-220.92%
EBITD / Share (TTM)$-1.30
ROE (5Y Avg)-206.78%
Cash Flow / Share (Annual)$-0.44
P/B Ratio14.28x
P/B Ratio (Quarterly)10.13x
Net Income / Employee (Annual)$-14
Net Interest Coverage (TTM)-40.24x
ROA (TTM)-283.54%
EPS Incl Extra (Annual)$-1.34
Current Ratio (Annual)0.31x
Quick Ratio (Quarterly)0.28x
3-Month Avg Trading Volume0.97M
52-Week Price Return65.80%
Tangible BV / Share (Quarterly)$-0.07
P/S Ratio (Annual)86.38x
Asset Turnover (Annual)0.09x
52-Week High$3.84
EPS Excl Extra (Annual)$-1.34
Tangible BV CAGR (5Y)-36.09%
26-Week Price Return2.56%
Quick Ratio (Annual)0.28x
13-Week Price Return48.84%
Total Debt / Equity (Annual)1.42x
Current Ratio (Quarterly)0.31x
Enterprise Value$98.019
Book Value / Share Growth (5Y)-57.11%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-2336.49%
Cash / Share (Annual)$0.25
3-Month Return Std Dev99.58%
Net Income / Employee (TTM)$-14
ROE (Last FY)-536.56%
Net Interest Coverage (Annual)1.51x
EPS Basic Excl Extra (Annual)$-1.34
Total Debt / Equity (Quarterly)1.42x
EPS Incl Extra (TTM)$-1.57
ROI (TTM)-172.32%
Revenue / Share (Annual)$0.06
Tangible BV / Share (Annual)$0.11
Forward P/E2.85x
Price vs S&P 500 (52W)31.17%
Year-to-Date Return18.08%
5-Day Price Return28.00%
EPS Normalized (Annual)$-1.34
ROA (5Y Avg)-351.92%
Net Profit Margin (Annual)-2336.49%
Month-to-Date Return50.23%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-1.30
Operating Margin (Annual)-1830.61%
LT Debt / Equity (Annual)0.38x
ROI (5Y Avg)-135.89%
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-1.57
P/B Ratio (Annual)10.13x
Book Value / Share (Annual)$1.12
Price vs S&P 500 (13W)46.46%
Beta2.07x
ROE (TTM)-195.76%
52-Week Low$1.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NRXPNRX Pharmaceuticals, Inc. Common Stock | — | — | — | — | $3.20 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
NRX Pharmaceuticals is a clinical-stage pharmaceutical company developing small-molecule therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company has commercialized ZYESAMI (Aviptadil) for COVID-related respiratory failure and is advancing NRX-100/101, a sequential treatment regimen for bipolar depression in patients with acute suicidal ideation. Its pipeline targets unmet needs in critical care and psychiatry.